AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04522830
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual dosing of matching placebo on days 1 and 2 - Day 1 - 1 drop every 15 minutes for the first hour of initiation of treatment then every hour for the balance of the day until bedtime.~Day 2 - 1 drop every 2-3 hours for a total of 6 times during the day. The parallel group assignment will only be maintained until the completion of a minimum of 48 hours of blinded study drug dosing, at which point all subjects will receive the active treatment.~Day 3 - 1 drop every 15 mins for the first hour of the day, then every hour for the balance of the day until bedtime.~Days 4 through 10 - 1 drop every 3-4 hours for a total of four times during the day.
Trial: NCT03733301
Drug: Topical corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as standard-of-care.
Trial: NCT00483119
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: cyclophosphamide dose of 2mg/kg/day divided into three-times daily oral administration
Trial: NCT00937859
Drug: SER120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SER120
Trial: NCT00937859
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04668066
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo given intravenously or subcutaneous
Trial: NCT00707941
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Children \< 12 years, suspension by weight (kg) as follows: Dose X 5 days Volume (ml) \< 15kg = 30 mg PO BID (2.5 ml) 15kg - 22kg = 45 mg PO BID (3.75 ml) 23kg - 39kg = 60 mg PO BID (5 ml)~Patients≥12 years: 75 mg capsules as follows 1 cap (75 mg) PO BID X 5 days~≥ 40 75 mg PO BID 6.25
Trial: NCT02246465
Drug: RXI-109
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01134705
Drug: Placebo Nasal Aerosol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HFA Vehicle Aerosol
Trial: NCT01125449
Drug: Ascorbic acid (vitamin C)
RxNorm normalized name: Ascorbic acid (vitamin C), plain
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous administration of up to 1.5gm/kg of ascorbic acid, twice weekly for up to 12-weeks.
Trial: NCT01215097
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once a day
Trial: NCT01779466
Drug: Placebo (not active)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03196362
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet of placebo will be given twice daily
Trial: NCT04562428
Drug: Xiang Sha Liu Jun Zi Decoction dry powder
RxNorm normalized name: Calagel Reformulated Jun 2019
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the principles of Chinese medicine treatment areinvigorating Pi, regulating qi, dissipating dampness and appetizing wei
Trial: NCT04562428
Drug: XSLJZ Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XSLJZ Placebo
Trial: NCT01562093
Drug: corticosteroid nasal spray
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fluticasone furoate 55 µg (formula containing anhydrous glucose, dispersible cellulose, polysorbate 80, benzalkonium chloride, disodium edetate, purified water) once daily in each nostril for 3 months
Trial: NCT01562093
Drug: placebo nasal spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: formula containing anhydrous glucose, dispersible cellulose, polysorbate 80, benzalkonium chloride, disodium edetate, and purified water, once daily in each nostril for 3 months
Trial: NCT02203773
Drug: ABT-199
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-199 is taken orally once daily starting on Day 2 of cycle 1 and begin on day 1 of every other cycle thereafter. This is a dose escalation study, therefore the dose of ABT-199 will change.
Trial: NCT04198051
Drug: adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Form、dosage and frequency： Gastric cancer was given the SOX regimen (oxaliplatin + tegafur regimen,oxaliplatin 130mg/m2 intravenous infusion, the 1st day; tegafur 80mg/ m2/d orally Bid, the 1st to 14th day, every 21 days is one cycle) or XELOX regimen (oxaliplatin + capecitabine regimen，oxaliplatin 130mg/m2 intravenous infusion, the 1st day; capecitabine 1000mg/m2/d orally Bid, the 1st to 14th day, every 21 days is one cycle).~Colon cancer was given the XELOX regimen (the dosage、frequency and administration are the same as the gastric cancer) or FOLFOX regimen (oxaliplatin + calcium folinate + fluorouracil regimen，oxaliplatin 85mg/m2 intravenous infusion, the 1st day; calcium folinate 400 mg/m2 intravenous infusion, the 1st day; fluorouracil 400 mg/m2 intravenous infusion, the 1st day, then 1200 mg/m2/d × 2d continuous intravenous infusion，every 14 days is one cycle).~Duration：through chemotherapy completion，about six months.
Trial: NCT02146534
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo will be taken PO BID
Trial: NCT01614691
Drug: SPARC1203
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active
Trial: NCT01614691
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00566397
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00346970
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets
Trial: NCT03480243
Drug: Erythromycin
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * Pharmaceutical Form: film-coated tablet~* Route of Administration: Oral use
Trial: NCT05429749
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline 250ml is administered between the admission day and the surgery day.
Trial: NCT01195831
Drug: Xamiol® gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily application
Trial: NCT00486291
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matched placebo
Trial: NCT01209702
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to tocilizumab administered intravenously every 4 weeks
Trial: NCT00973713
Drug: RAD001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10mg/d
Trial: NCT03934099
Drug: LC350189 formulated capsule
RxNorm normalized name: Tarsum Reformulated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xanthine Oxidase Inhibitor
Trial: NCT03934099
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT04074161
Drug: Placebo (semaglutide)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered once weekly for 68 weeks
Trial: NCT00950820
Drug: Oxaliplatin, Capecitabine, Panitumumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Panitumumab at a dose of 9 mg/kg BW every three weeks will be administered on day 1 of each cycle just prior to administration of chemotherapy.~The XELOX regimen is defined as a 2 hour infusion of oxaliplatin 130 mg/m² on day 1 followed by capecitabine 1000 mg/m² bid per os. Capecitabine administration will commence on the evening of day 1 and complete after the morning dose on day 15.
Trial: NCT00950820
Drug: Oxaliplatin, Capecitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The XELOX regimen is defined as a 2 hour infusion of oxaliplatin 130 mg/m² on day 1 followed by capecitabine 1000 mg/m² bid per os. Capecitabine administration will commence on the evening of day 1 and complete after the morning dose on day 15.
Trial: NCT00160901
Drug: two complex naturopathic add-on therapies, leaflet 5-a-day
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02390505
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00518089
Drug: placebo eye drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day 1 = 1 drop of study medication every 2hrs up to 8 times total; day 2-5 = 1 drop twice daily
Trial: NCT05517746
Drug: BAY2395840 tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablets, oral administration
Trial: NCT05517746
Drug: BAY2395840 oral solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: solution, oral administration
Trial: NCT05517746
Drug: Placebo oral solution
RxNorm normalized name: Placebo Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching BAY2395840, oral administration
Trial: NCT05517746
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching BAY2395840, oral administration
Trial: NCT03112577
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT02177071
Drug: AZATHIOPRINE
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02177071
Drug: MERCAPTOPURINE
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02177071
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01187511
Drug: GSK561679
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verucerfont is a corticotropin releasing hormone receptor 1 (CRF1) antagonist.
Trial: NCT01187511
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is an inactive tablet design to look exactly like GSK561679
Trial: NCT01048034
Drug: Erythropoetin
RxNorm normalized name: Erythropoetin zeta
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For those patients not responding to Azacitidine alone, the combination of Azacitidine and erythropoetin 60 000 U / week for 16 weeks will be given.
Trial: NCT01733680
Drug: amiloride
RxNorm normalized name: Amiloride
DrugBank: Amiloride (DB00594)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will take either amiloride hydrochloride or placebo for 8 weeks.
Trial: NCT02255045
Drug: Meloxicam
RxNorm normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 Meloxicam Vaginal Ring (MVR) for 4-6 days
Trial: NCT02255045
Drug: Diclofenac Potassium
RxNorm normalized name: Diclofenac Potassium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 tablet 50 mg diclofenac every 12 hours for 4-6 days
Trial: NCT02255045
Drug: Placebo Oral
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 placebo tablet every 12 hours for 4-6 days
Trial: NCT02255045
Drug: Placebo Vaginal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 placebo vaginal ring for 4-6 days
Trial: NCT03502356
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: In this group, patients will receive standard antibiotic prophylaxis CEFAZOLIN (at a dose of 1 g) and azithromycin (at a dose of 1g) 2 hours preoperative.
Trial: NCT02424578
Drug: Diclofenac Capsules low dose
RxNorm normalized name: diclofenac Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02424578
Drug: Diclofenac Capsules high dose
RxNorm normalized name: diclofenac Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03899467
Drug: GT0918
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anti-tumor activity
Trial: NCT01857934
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given intravenously (IV)
Trial: NCT00005607
Drug: FOLFIRI regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00005607
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00005607
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00674440
Drug: F-DOPA
RxNorm normalized name: dopa, DL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.08-0.16 mCi/kg once
Trial: NCT03063931
Drug: Placebo: Lactose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This clinical trial compares magnesium and placebo for the prevention of neuropathic pain induced by mastectomy assessed with a (0-10) numerical pain rating scale
Trial: NCT00005658
Drug: Glycine
RxNorm normalized name: Glycine
DrugBank: Glycine (DB00145)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01247272
Drug: Fluoxetine Hydrochloride
RxNorm normalized name: Fluoxetine Hydrochloride
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 90 mg Capsules
Trial: NCT01247272
Drug: PROZAC WEEKLY®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 mg Capsules
Trial: NCT01436929
Drug: Silymarin
RxNorm normalized name: silymarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silymarin 140mg 1tab bid for 8 weeks
Trial: NCT01436929
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 1tab bid
Trial: NCT02213861
Drug: SHAPE
RxNorm normalized name: Panshape M
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical gel
Trial: NCT01163227
Drug: Placebo (single and multiple doses)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01163227
Drug: AQW051 2 mg (single and multiple doses)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01163227
Drug: AQW051 15mg (single and multiple doses)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01163227
Drug: AQW051 100mg (single dose), and 50mg (multiple doses)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02256709
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02256709
Drug: BIBP 5371 CL tablet high dose
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02256709
Drug: Placebo drinking solution
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04105504
Drug: Glutathione
RxNorm normalized name: Glutathione
DrugBank: Glutathione (DB00143)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glutathione capsule (500 mg), were taken once daily by the subjects.
Trial: NCT04105504
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral capsule were taken once daily by the subjects.
Trial: NCT01857934
Drug: doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00732537
Drug: inhaled Nitric Oxide
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iNO started at 20 ppm for 1 hour, then weaned hourly over the next 4 hours (20 ppm to 10 to 5 to 2.5 to 1 to off). If \>5% drop in oxygen saturation was observed during weaning, study gas was increased to the previous concentration and weaning done 2 hourly. If \> 5% drop in oxygen saturation or \>5% Methemoglobin was observed during initial administration, the study gas would be weaned over 30 minutes and the infant would exit. The iNO was introduced into an oxygen hood (Oxydome ™ disposable hood from Maxtex ® Inc.) using an INOvent (Datex-Ohmeda). The INOvent ® was connected to the oxyhood by placing the injector module inline on the dry side of the humidifier chamber. Monitoring of O2, NO2, NO was done by placing the end of the sample line inside the oxyhood. A Masking Shield covered the Display/Control Panel and Cylinder Gauges, in order to maintain masking of the intervention. Only the respiratory therapist and research coordinator was aware of the allocation assignment.
Trial: NCT03643068
Drug: KSP-QRH-E3-IRDye800 (Peptide 919288G), 0.6 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The investigational agent to be used in this study is KSP/QRH dimer: a fluorescently-labeled peptide dimer composed of a 14-amino acid sequence \[Lys-Ser-Pro-Asn-Pro-Arg-Phe\] and \[Gln-Arg-His-Lys-Pro-Arg-Glu\] attached via a PEG3, Lys and Cys linker \[PEG3\]2-Lys-Cys to a near-infrared fluorophore, IRDye800CW (0.6 mg dose).
Trial: NCT02094365
Drug: vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03643068
Drug: KSP-QRH-E3-IRDye800 (Peptide 919288G), 1.8 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The investigational agent to be used in this study is KSP/QRH dimer: a fluorescently-labeled peptide dimer composed of a 14-amino acid sequence \[Lys-Ser-Pro-Asn-Pro-Arg-Phe\] and \[Gln-Arg-His-Lys-Pro-Arg-Glu\] attached via a PEG3, Lys and Cys linker \[PEG3\]2-Lys-Cys to a near-infrared fluorophore, IRDye800CW (1.8 mg dose).
Trial: NCT02280018
Drug: JNJ-49122944, 5 milligram (mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive single dose of 5 mg JNJ-49122944, administered as a 22.2 mL IV infusion over 45 minutes on Day 1.
Trial: NCT02280018
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo matched to JNJ-49122944, administered as a 22.2 mL IV infusion over 45 minutes on Day 1.
Trial: NCT00704236
Drug: Coptis Chinensis, Astragalus mambranesceus, Lonicera Japonica (Traditional Chinese Treatment)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg of Coptis Chinensis, 30 mg of Astragalus mambranesceus and 120 mg of Lonicera Japonica
Trial: NCT00704236
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03202615
Drug: F (ferrous sulphate)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: FerroGrad by Abbott Dosage: one capsule three times /day containing150 mg of dried ferrous sulfate capsules (Ferrofol capsules, Eipico, Egypt), with placebo sachets.
Trial: NCT01215968
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered subcutaneously
Trial: NCT00865280
Drug: PTK 0796
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTK 0796 100 mg for injection; PTK 0796 tablet 150 mg
Trial: NCT00050050
Drug: Drug therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00948441
Drug: 25% ethanol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study Lock -25% Ethanol- The ethanol lock therapy consists of placing up to 2.3 ml of 25% ethanol into the central venous catheter and allowing it to dwell for 4 to 12 hours per day.
Trial: NCT00947882
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mannitol 50 mg/mL solution
Trial: NCT02644876
Drug: Placebo inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo inhalation will be administered by inhalation (water for injection 0.5 ml, mixed with normal saline 5.5 ml) once every 12 hours from the night before surgery till the second day after surgery. The total number of inhalation is seven times. Study drug inhalation is performed with the high-flow oxygen-driven method for the non-intubated patients or with the atomizing inhalation device of ventilator for the intubated patients.
Trial: NCT01206218
Drug: FLOT Regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FLOT Regimen: 5-fluorouracil, Oxaliplatin, Docetaxel
Trial: NCT01206218
Drug: FLO Regimen or FLOT Regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FLO Regimen: 5-fluorouracil, Oxaliplatin FLOT Regimen: 5-fluorouracil, Oxaliplatin, Docetaxel
Trial: NCT01906762
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This protocol prepared by a nurse and labeled as Drug A. Since the rapid injection of Acetaminophen can result in hypotension, therefore based on the Apotel Injection Instruction, it must be infused slowly within 15 minutes.
Trial: NCT04976543
Drug: nadroparin calcium-warfarin sequential anticoagulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The NWS therapy group were given a subcutaneous injection of nadroparin calcium every 12 hours for 1 month and switched to warfarin for 5 months. Warfarin was initiated at least 5 days before nadroparin calcium was stopped. International normalized ratio (INR) was detected every 3-4 days and adjusted carefully by 0.75mg dosage until achieve the target level of 2-3.
Trial: NCT03126318
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile water with a final buffer of 25 mM Histidine, 8.5% (w/v) trehalose and 0.05% PS80
Trial: NCT00666016
Drug: TRO19622
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRO19622 500 mg once a day before noon meal during 6 weeks
Trial: NCT02784067
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucraid placebo
Trial: NCT01420211
Drug: Primovist® 0,25 mmol/ml solution for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous bolus injection of 25 µmol/kg (=0,1 ml/kg) body weight Primovist® and blood sampling before (serum blank) and 6, 11, 21, 31, 45, 65, 95, 125 min and 3, 4, 6, 8, 12, 24 and 48 h after drug administration
Trial: NCT02211170
Drug: BIBR 796 BS, low dose
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02211170
Drug: BIBR 796 BS, high dose
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02211170
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00104520
Drug: AZLI 75 mg two times a day (BID)/three times a day (TID)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00104520
Drug: Placebo two times a day (BID)/three times a day (TID)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01080365
Drug: SKI-606 (Bosutinib)
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 500 mg commercial formulation film coated tablet, administered once daily